Plant Name: Medicago sativa
Taxonomic Information:
Plant ID: NPO18321
Plant Latin Name: Medicago sativa
Taxonomy Genus: Medicago
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
3879
Plant-of-the-World-Online:
30234961-2
Used in Medicines:
Country/Region:
China; Argentina; India; Turkmenistan; ChileTraditional Medicine System:
Unani; TCM; Homeopathy; AyurvedaMedicinal Functions:
Anodyne; Antibacterial; Antiscorbutic; Aperient; Diuretic; Emetic; Febrifuge; Haemostatic; Hypoglycaemic; Nutritive; Stimulant; Tonic
Geographical Distribution:
Brazil; Afghanistan; Italy; Bangladesh; Sudan; Nepal; Mongolia; France; Somalia; Ireland; Argentina; Bolivia; Norway; Ecuador; Turkmenistan; Uzbekistan; Saudi Arabia; Australia; Iran; Algeria; Cuba; Turkey; Venezuela; Austria; Russia; United States; Guatemala; China; Chile; Oman; Belgium; Germany; Dominican Republic; Iraq; Kazakhstan; Spain; Ukraine; Netherlands; Libya; Denmark; Poland; Finland; New Caledonia; Mauritius; Morocco; Sweden; Belarus; Switzerland; Uruguay; New Zealand; Yemen; Haiti; Bulgaria; Pakistan; Romania; Albania; Angola; Portugal; Chad; Mexico; Egypt; Tajikistan; South Africa; India; Peru; United Kingdom; Tunisia; Djibouti; Colombia; Greece; Sri Lanka; Hungary; Cyprus
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TDP1; BLM; NQO1; | |
| CA7; CA4; CA12; | |
| ESR1; ESR2; | |
| SLCO1B1; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2C9; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | NQO1 | Quinone reductase 1) | P15559 | CHEMBL3623 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.228E-08 | 1.356E-03 | CA12, CA4, CA7 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.948E-07 | 3.109E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.709E-07 | 5.286E-03 | CA12, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.797E-06 | 6.520E-03 | CA12, CA4, CA7 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.768E-06 | 6.520E-03 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.103E-06 | 6.543E-03 | BLM, CA12, CA4, CA7, ESR1, ESR2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 8.381E-08 | 1.928E-06 | CA12, CA4, CA7 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 6.883E-04 | 7.916E-03 | ESR1, ESR2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.296E-03 | 9.935E-03 | ESR1, ESR2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | NQO1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
